|

Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.

RECRUITINGN/ASponsored by Universitair Ziekenhuis Brussel
Actively Recruiting
PhaseN/A
SponsorUniversitair Ziekenhuis Brussel
Started2023-07-28
Est. completion2026-06-01
Eligibility
Age60 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05950867

Summary

To investigate to what extent chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) is part of early non-cardiac manifestations of wild-type TTR cardiac amyloidosis (wtTTR-CA). Consequently, explore whether this could ultimately lead to faster diagnosis and clinical outcome of wild-type TTR cardiac amyloidosis (wtTTR-CA).

Eligibility

Age: 60 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) without well-defined etiology.
* Age: \>= 60 years
* Male and female gender
* Written informed consent

Exclusion Criteria:

* Known cause of polyneuropathy
* Other types of peripheral neuropathy than chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN).
* Patients younger than 60 years

Conditions3

AmyloidosisHeart DiseasePolyneuropathy

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.